Skip to content

Study · Randomized controlled trial · n = 1,583 · 2023

5 results

Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.

Wilkinson L, Holst-Hansen T, Laursen PN, Rinnov AR, Batterham RL, Garvey WT

Obesity (Silver Spring, Md.)1 Sept 2023Cited by 17 (Europe PMC)

PMID37605636 (opens in a new tab)DOI10.1002/oby.23842 (opens in a new tab)PepBankPUB-37605636
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight in STEP 1, semaglutide 2.4 mg reduced the 10-year type 2 diabetes relative risk score more than placebo (-61.1% versus -12.9%).

    In plain wordsIn adults with overweight or obesity, semaglutide cut the calculated 10-year diabetes risk score by more than placebo did.

    Peptide
    Semaglutide
    Outcome
    Decrease10-year T2D relative risk score change, STEP 1
    Study

    n = 1,583

    Comparator
    Placebo
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Relative risk score change
    −61.1%
    semaglutide
    Relative risk score change
    −12.9%
    placebo

    Source sentences

    Summary
    In STEP 1 (N = 1583), relative risk score reductions were greater with semaglutide versus placebo (semaglutide: -61.1%; placebo: -12.9%; p < 0.0001).
    1 context sentence
    Summary · context
    STEP 1 (68 weeks) and 5 (104 weeks) randomized participants to semaglutide 2.4 mg or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults in the STEP 4 semaglutide run-in, the 10-year type 2 diabetes risk score fell from 20.6% to 11.1%.

    In plain wordsIn adults on semaglutide, the calculated 10-year diabetes risk score fell during the first 20 weeks.

    Peptide
    Semaglutide
    Outcome
    Decrease10-year T2D risk score during 20-week semaglutide run-in, STEP 4
    Study

    n = 776

    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneous · 20 weeksAs given in this study (human).

    Measurements

    Risk score
    20.6%
    baseline
    Risk score
    11.1%
    end of run-in

    Source sentences

    Summary
    Risk scores during the STEP 4 run-in period (N = 776) were reduced from 20.6% to 11.1%
    1 context sentence
    Summary · context
    STEP 4 included a 20-week semaglutide run-in followed by randomization to 48 weeks of continued semaglutide or withdrawal (placebo).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight in STEP 5, the reduction in 10-year type 2 diabetes risk score with semaglutide 2.4 mg was maintained to week 104 (-60.0% versus 3.5% with placebo).

    In plain wordsIn adults with overweight or obesity, the lower calculated diabetes risk with semaglutide lasted to week 104, unlike with placebo.

    Peptide
    Semaglutide
    Outcome
    Decrease10-year T2D relative risk score change, STEP 5
    Study

    n = 295

    Comparator
    Placebo
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneous · 104 weeksAs given in this study (human).

    Measurements

    Relative risk score change
    −60%
    semaglutide
    Relative risk score change
    3.5%
    placebo

    Source sentences

    Summary
    These reductions were maintained to week 104 in STEP 5 (N = 295; semaglutide: -60.0%; placebo: 3.5%; p < 0.0001).
    1 context sentence
    Summary · context
    STEP 1 (68 weeks) and 5 (104 weeks) randomized participants to semaglutide 2.4 mg or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults in STEP 4, continued semaglutide lowered the 10-year type 2 diabetes risk score further (-32.1%), while withdrawal to placebo raised it (+40.6%).

    In plain wordsIn adults on semaglutide for 20 weeks, staying on it kept the calculated diabetes risk score falling; switching to placebo made it rise.

    Peptide
    Semaglutide
    Outcome
    Decrease10-year T2D relative risk score change, continued semaglutide versus withdrawal, STEP 4
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Risk score
    7.7%
    continued semaglutide, week 68
    Risk score
    15.4%
    withdrawal, week 68
    Relative risk score change
    −32.1%
    semaglutide
    Relative risk score change
    40.6%
    placebo

    Source sentences

    Summary
    Risk scores during the STEP 4 run-in period (N = 776) were reduced from 20.6% to 11.1% and further to 7.7% at week 68 with continued semaglutide, increasing to 15.4% with withdrawal (relative risk score change: semaglutide: -32.1%; placebo: +40.6%; p < 0.0001).
    1 context sentence
    Summary · context
    STEP 4 included a 20-week semaglutide run-in followed by randomization to 48 weeks of continued semaglutide or withdrawal (placebo).
  5. 05HumanRandomized controlled trialOther

    In the semaglutide trials, risk score reductions mirrored weight loss.

    In plain wordsIn these trials, the fall in diabetes risk score followed the weight loss.

    Peptide
    Semaglutide
    Outcome
    Not applicableLink of risk score reduction with weight loss
    Study

    n: not reported in source

    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Risk score reductions mirrored weight loss.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03693430

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Novo Nordisk A/Sn = 3045 Oct 2018 to 23 Mar 2021

Overweight · Obesity

Trial pageClinicalTrials.govUpdated 6 Jul 2023
CompletedPhase 3Results postedNCT03548987

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Novo Nordisk A/Sn = 9024 Jun 2018 to 20 Mar 2020

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 19 Jan 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.